CML and the WHO: Why?
Ellin Berman(Memorial Sloan Kettering Cancer Center), Brian Druker(Oregon Health & Science University), Vivian G. Oehler(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ravi Bhatia(University of Alabama at Birmingham), Moshe Talpaz(University of Michigan), Tiffany Tanaka(UC San Diego Health System), B. Douglas Smith(Johns Hopkins University), Jörge E. Cortes(Augusta University Health), Neil P. Shah(University of California, San Francisco), Michael J. Mauro(Memorial Sloan Kettering Cancer Center), Michael W. Drazer(Susan Thompson Buffett Foundation), Jessica K. Altman(Northwestern University), Leland Metheny(Cancer Institute (WIA)), Iskra Pusic(Washington University in St. Louis), Maria L. Amaya(University of Colorado Denver), Srinivas K. Tantravahi(University of Utah), Keith W. Pratz(University of Pennsylvania), Lori J. Maness(Susan Thompson Buffett Foundation), Sanjay Mohan(Breast Cancer Research Foundation), Michael Styler(Fox Chase Cancer Center), Kendra Sweet(Moffitt Cancer Center), Peter Curtin(City Of Hope National Medical Center), Onyee Chan(Moffitt Cancer Center), Kebede H. Begna(Mayo Clinic), William Shomali(Stanford Medicine), Daniel J. DeAngelo(Dana-Farber Cancer Institute), David T. Yang(University of Wisconsin–Madison), Robert H. Collins(Texas Oncology), Jerald P. Radich(University of Washington), Steven Tsai(University of Colorado Cancer Center), JOSEPH EARLE MOORE(Unknown), Jeanna Welborn(UC Davis Comprehensive Cancer Center), Jennifer E. Vaughn(The Ohio State University), Michal G. Rose(Yale Cancer Center), Michael W. Deininger(Versiti Blood Center of Wisconsin)
Cited by 14
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k